Evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas’ disease

Read full text Summarise with VIRAT
Authors: Dmitry Abramov, Abdul Mannan Khan Minhas, Tamás Alexy, Patrícia O. Guimarães, M L Mitja Lainscak, Peder Langeland Myhre
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Heart failure is a common manifestation of Chagas’ disease and results in significant morbidity and mortality in affected patients. In light of limited data on therapeutic options for heart failure due to Chagas’ disease, the PARACHUTE-HF trial aimed to compare the effects of sacubitril/valsartan versus enalapril on clinical endpoints and changes in natriuretic peptides in this population. This mini-review contextualizes the results of the trial, which demonstrated that sacubitril/valsartan led to significant improvements in outcomes driven primarily by a reduction in natriuretic peptides.

Fields of Study & Subjects

Heart Failure Treatment and Management Trypanosoma species research and implications Cardiac Fibrosis and Remodeling

Publication details

Journal / source
Heart Failure Reviews
Volume
31
Issue
1
Pages
49
Publication date
30 March 2026
Language
EN